The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months

PHASE3CompletedINTERVENTIONAL
Enrollment

661

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions
Benign Prostatic Hyperplasia
Interventions
DRUG

Silodosin

8 mg daily

Trial Locations (79)

Unknown

Birmingham

Huntsville

Tucson

Anaheim

Carmichael

Culver City

Fresno

Irvine

La Jolla

Laguna Woods

Long Beach

Newport Beach

San Bernardino

San Diego

Tarzana

Torrance

Aurora

Wheat Ridge

Waterbury

Aventura

Clearwater

Coral Gables

New Port Richey

Ocala

Orlando

Pensacola

Plantation

Tampa

West Palm Beach

Marietta

Chicago

Melrose Park

Peoria

Evansville

Fort Wayne

Des Moines

Overland Park

Greenbelt

Boston

Saint Joseph

Edina

Jackson

Kansas City

Missoula

Las Vegas

Lawrenceville

Voorhees Township

Albuquerque

Albany

Bay Shore

Garden City

Kingston

Manhasset

New York

Poughkeepsie

Staten Island

Williamsville

Charlotte

Concord

Salisbury

Winston-Salem

Cincinnati

Bethany

Portland

Lancaster

Providence

Greer

Mt. Pleasant

Myrtle Beach

Austin

Dallas

San Antonio

Salt Lake City

Norfolk

Lakewood

Seattle

Tacoma

Madison

Milwaukee

Sponsors
All Listed Sponsors
lead

Watson Pharmaceuticals

INDUSTRY

NCT00224133 - The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months | Biotech Hunter | Biotech Hunter